All In Biotech

Drug Trial Radar · NCT02750709

Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin

A Single Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing of Nitisinone 10 mg Compared to the Reference Formulation Orfadin 10 mg in at Least 18 Healthy Male and Female Subjects Under Fasting Conditions

Last checked: Nov 19, 2026Latest source record: Mar 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Oct 2015

Primary completion

Dec 2015

Study completion Jan 2016

Sponsor

Lead sponsor
Cycle Pharmaceuticals Ltd.Industry
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Nitisinone 10 mg Tablets (Test Product 1 (TP1)) and Nitisinone 10 mg Tablets High Compritol (Test Product 2 (TP2)) are bioequivalent to the reference product Orfadin 10 mg capsules.

Conditions

  • Hereditary Tyrosinemia, Type I

Interventions

  • NitisinoneDrug

    A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.

  • Nitisinone 10 mg Tablet High CompritolDrug

    A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.

  • OrfadinDrug

    A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours
  2. Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 120 Hours Post-dose (AUC(0-120))Time frame: 0, 0.25, 0.50, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)

    Bloemfontein, Free State, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.